海西新药,福建海西新药,福建海西新药创制股份有限公司,药品研发,药品生产,药品销售,新药研发,创新药

Haixi Pharmaceuticals

Fujian Haixi Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”, 02637.HK) was founded in 2012 as a commercial-stage innovative pharmaceutical company covering the entire industrial chain of R&D, clinical research, manufacturing and commercialization. The company was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on October 20, 2025, and was included in the Hang Seng Stock Connect Hong Kong on March 9, 2026.

Adhering to the development philosophy of “Generics Empower Innovation, Innovation Drives the Future”, the company pursues a coordinated strategy of generic drugs and innovative drugs.

In the field of generic drugs, the company focuses on the R&D of first-to-file generics, difficult-to-make generics and high-value generics. As of March 2026,

Haixi Pharmaceuticals

Product

Mosapride Citrate Tablets

This product is used to improve gastrointestinal symptoms caused by reduced gastrointestinal motility such as functional dyspepsia and chronic gastritis, including heartburn,

Amlodipine atorvastatin calcium tablets

Suitable for patients who require combination therapy of amlodipine and atorvastatin. Amlodipine is used to treat hypertension and coronary heart disease; Atorvastatin is used to treat hypercholesterolemia and coronary heart disease.

Cinacalcet Hydrochloride Tablets

This product is used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving maintenance dialysis.

Valsartan/Amlodipine tablets (I)

For the treatment of essential hypertension. This product is indicated in patients whose blood pressure is not adequately controlled by monotherapy.

Bisoprolol Fumarate and Amlodipine Besilate Tablets

As a substitution therapy in hypertension, indicated for patients whose blood pressure is well controlled with the same doses of bisoprolol and amlodipine given separately.

Ascitalopram Oxalate Tablets

For the treatment of depressive disorders, and for panic disorder with or without agoraphobia.

News

wAMD DRUG PROJECT HXP056 COMPLETED ENROLLMENT FOR PHASE I CLINICAL STUDY AND INITIATED PHASE 2 STUDY

Information disclosure column on responsibility for the prevention and control of hazardous waste pollution

Good news! Amlodipine atorvastatin calcium tablets won the bid for the eighth batch of national centralized drug procurement

Haixi New Pharmaceutical has passed the consistency evaluation of generic drugs. The product amlodipine atorvastatin calcium tablets (trademark name: Haihuitong®) has won the first place.

Announcement of the overall change of Fujian Haixi New Drug Creation Co., Ltd. to a limited company

With the approval of Fujian Provincial Market Supervision and Administration, from November 15, 2022, Fujian Haixi New Pharmaceutical Creation Co., Ltd. has been changed to Fujian Haixi New Pharmaceutical Creation Co., Ltd.

About Us

Technology

Product

News

Investor

Attract Talents

Contact Us

Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063

Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.